Showing 5141-5150 of 9751 results for "".
- J&J Seeks FDA Approval for Pediatric Tremfya Indicationshttps://practicaldermatology.com/news/jj-seeks-fda-approval-pediatric-tremfya-indications/2468706/Johnson & Johnson (J&J) has submitted supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Tremfya (guselkumab), seeking approval for pediatric indications. Tremfya, the first approved monoclonal antibody IL-23 inhibitor that select
- OLYMPIA 1: Nemolizumab Shows Improvements in Prurigo Nodularis Symptomshttps://practicaldermatology.com/news/olympia-1-nemolizumab-shows-improvements-prurigo-nodularis-symptoms/2468705/Results from a multicenter phase 3 clinical trial indicated that nemolizumab monotherapy significantly reduces pruritus and nodular lesions in adults with moderate to severe prurigo nodularis (PN). Researchers for the OLYMPIA 1 trial evaluated the efficacy and safety of nemolizumab in 286
- Study Links Skin Microbiota and AD Alleviation via Melatoninhttps://practicaldermatology.com/news/study-links-skin-microbiota-and-ad-alleviation-melatonin/2468664/A new study published in the Journal of Allergy and Clinical Immunology indicates melatonin has been shown to reduce atopic dermatitis (AD) symptoms by altering skin microbiota composition, with short-chain fatty acids (SCFAs) such as propionic acid playing a key role in this process. Alth
- Study: TPC2 Ion Channel Key Driver of Melanoma Progressionhttps://practicaldermatology.com/news/study-tpc2-ion-channel-key-driver-melanoma-progression/2468665/New research has succeeded in identifying a critical regulator of melanoma progression. The research, published by a group from Ludwig-Maximilians-Universität München in Nature Communications, highlights how TPC2 influences intracellular trafficking pathways that drive melanoma c
- Study Links Psoriasis Severity to Increased Heart Disease Riskhttps://practicaldermatology.com/news/study-links-psoriasis-severity-increased-heart-disease-risk/2468660/Psoriasis severity is associated with increased cardiovascular risk, according to new research, with systemic inflammation functioning as a key mediator. Data from two cohorts—the Psoriasis Atherosclerosis and Cardiometabolic Disease Initiative (PACI) and the Stockholm Psoriasis Cohort (SP
- Dupilumab Shows Long-Term Survival Rates in Treating Moderate-to-Severe Atopic Dermatitishttps://practicaldermatology.com/news/dupilumab-shows-long-term-survival-rates-treating-moderate-severe-atopic-dermatitis/2468646/A recent literature review of published studies suggested that dupilumab maintained survival rates of 80–90% at 1, 2, and 3 years, significantly exceeding the 20-41% rates observed for cyclosporine and methotrexate during comparable periods. "The aim of this literature review is to describ
- SDPA: Strategic Supplement Strategies for the Derm PAhttps://practicaldermatology.com/news/sdpa-strategic-supplement-strategies-derm-pa/2468638/Sara Wilchowski, DMSc, MPAS, PA-C, presented “Strategic Supplement Strategies for the Derm PA” at SDPA’s 22nd Annual Fall Dermatology Conference in Las Vegas. The lecture explored the role of nutraceuticals and alternative medicines in supporting patients in their overall wellness jour
- FDA Greenlights BIMZELX for Chronic Hidradenitis Suppurativahttps://practicaldermatology.com/news/fda-greenlights-bimzelx-chronic-hidradenitis-suppurativa/2468635/The Food and Drug Administration (FDA) has approved BIMZELX® (bimekizumab-bkzx) for adults with moderate-to-severe hidradenitis suppurativa (HS), making it the first treatment to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F). According to a press release f
- Acne Insights: Strategies and Solutions at 2024 SDPA Fallhttps://practicaldermatology.com/news/acne-insights-strategies-and-solutions-2024-sdpa-fall/2468634/The SDPA’s 22nd Annual Fall Dermatology Conference was held last week at the Fontainebleau in Las Vegas. Conference Medical Director Hilary Baldwin, MD, joined Shanna Miranti, MPAS, PA-C, in a discussion called “Acne Insights: Expert Strategies and Solutions from the Pros.” The presentatio
- Analyses: Ruxolitinib Cream Reduces AD Symptom Burden in 12 Hourshttps://practicaldermatology.com/news/analyses-ruxolitinib-cream-reduces-ad-symptom-burden-12-hours/2468615/Ruxolitinib cream significantly reduced skin pain and improved patient-reported outcomes (PROs) in individuals with mild-to-moderate atopic dermatitis (AD), with improvements sustained over 52 weeks, according to data from the TRuE-AD1 and TRuE-AD2 studies. Researchers the results publishi